Bhalavat Rajendra, Budrukkar Ashwini, Laskar Sarbani Ghosh, Sharma Dayanand, Mukherji Ashutosh, Chandra Manish, Mahantshetty Umesh, Pareek Vibhay, Bauskar Pratibha, Saraf Sonali
Department of Radiation Oncology, Jupiter Lifelines Hospital, Thane, India.
Department of Radiation Oncology, Tata Memorial Hospital, Parel, India.
J Contemp Brachytherapy. 2020 Oct;12(5):501-511. doi: 10.5114/jcb.2020.100385. Epub 2020 Oct 30.
Brachytherapy (BT) forms major treatment modality in squamous cell carcinoma of head and neck cancers (HNC). However, there is a dearth of literature and guidelines for the use in various indications. High-dose-rate brachytherapy (HDR-BT) in Indian scenario is an important treatment modality, and the recommendations in this guidelines aim to provide the necessary recommendations for the use of HDR-BT for uniform application across the country in patients with HNC.
A panel consisting of members of the Indian Brachytherapy Society (IBS), based on their clinical experience was invited. The process involved defining important steps, precautions, target volumes and indications, thorough literature review, and discussion with fellow members. The guidelines were established and formulated the recommendations for HDR-BT based on available evidences and individual experience for sites, relevant to Indian settings.
The IBS recommends the use of HDR brachytherapy as a part of treatment of head and neck tumors. The scope of these guidelines and recommendations included practical suggestions, ensuring efficient use of brachytherapy treatment as radical with external beam radiotherapy (EBRT) boost, palliative and adjuvant as definitive, or re-radiation as salvage for HNC in India. The IBS has made specific site-wise recommendations for previously untreated and recurrent HNC patients on their selection criteria, implant techniques, target volume definition, and HDR treatment parameters, such as time, dose rate, total dose, and fractionation schedules. Limited experience exists with HDR-BT in patients with head and neck cancers in India and across the globe.
IBS provided a consensus statement and guidelines for the head and neck brachytherapy and believed that these recommendations will overcome the fear of practicing radiation oncologists. This should generate interest amongst students and will help radiation oncologists all across the country to use the art of brachytherapy carefully in HNC patients, with better curative and salvage options.
近距离放射治疗(BT)是头颈部鳞状细胞癌(HNC)的主要治疗方式。然而,针对其在各种适应症中的应用,相关文献和指南较为匮乏。在印度,高剂量率近距离放射治疗(HDR - BT)是一种重要的治疗方式,本指南中的建议旨在为印度HNC患者使用HDR - BT提供必要的建议,以便在全国统一应用。
邀请了由印度近距离放射治疗学会(IBS)成员组成的小组,基于他们的临床经验开展工作。该过程包括确定重要步骤、预防措施、靶区体积和适应症,进行全面的文献综述,并与其他成员进行讨论。根据现有证据和与印度情况相关部位的个人经验,制定了指南并形成了HDR - BT的建议。
IBS建议将HDR近距离放射治疗作为头颈部肿瘤治疗的一部分。这些指南和建议的范围包括实用建议,确保近距离放射治疗作为外照射放疗(EBRT)增敏的根治性治疗、姑息性和辅助性确定性治疗,或作为印度HNC挽救性再放疗有效应用。IBS针对先前未治疗和复发的HNC患者,在选择标准、植入技术、靶区体积定义以及HDR治疗参数(如时间、剂量率、总剂量和分割方案)方面给出了具体的部位特异性建议。在印度乃至全球,HDR - BT在头颈部癌患者中的经验有限。
IBS提供了关于头颈部近距离放射治疗的共识声明和指南,并认为这些建议将消除放射肿瘤学家实施治疗的顾虑。这应能激发学生的兴趣,并帮助全国各地的放射肿瘤学家在HNC患者中谨慎运用近距离放射治疗技术,提供更好的治愈和挽救选择。